MannKind elevates Castanga to CEO; 23andMe recruits 5,000 women for study in 9 days

→  Financially-troubled MannKind elevated Michael Castanga from chief commercial officer to CEO. Matthew Pfeffer, the outgoing chief executive, will continue advising the company until the end of July. The company struggled its way through the clinic to end up with an inhaled insulin that diabetics have shunned.

→  Eisai and Charles River Laboratory have extended their preclinical discovery pact for another year. The two companies have been focusing on novel drugs for tropical and neurological diseases. Researchers will begin working with the Medicines for Malaria Venture, which is looking for new compounds to treat drug-resistant malaria.

→  Apogenix received the EMA’s PRIME (PRIority MEdicines) status for its glioblastoma drug asunercept based on the results of a Phase II trial in 86 patients. Only 23% of drugs that have applied since the program was introduced have been designated as PRIME.

The DTC-genomics pioneer 23andMe says it recruited 5,000 women for a fertility genetics study in just 9 days.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,100+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->